Summary: A large genetic analysis has pinpointed more than 400 genes associated with different patterns of unhealthy aging, from cognitive decline to metabolic dysfunction. The research shows that frailty is not a single uniform condition but a set of distinct subtypes driven by separate biological pathways.
These discoveries help explain why some people remain resilient into advanced age while others develop chronic diseases or functional decline earlier. Researchers say the results could inform personalized prevention and treatment strategies and advance efforts to target aging at its biological roots.
Key Facts
- Gene Discovery: 408 genes linked to frailty were identified, a major increase from the 37 genes previously reported.
- Frailty Subtypes: Researchers defined six subtypes, including poor cognition, metabolic dysfunction, disability, multiple diseases, unhealthy lifestyle, and limited social support.
- Therapeutic Potential: Findings support tailored interventions for different aging profiles rather than a single universal therapy.
Source: University of Colorado
Why some people age better than others
Many older adults preserve their physical and cognitive abilities into their 80s and 90s, while others face conditions such as diabetes, dementia, or mobility loss much earlier. Some recover from acute illness or injury quickly; others experience lasting decline after the same event. A new study led by researchers at the University of Colorado Boulder, published in Nature Genetics, offers new genetic insight into these divergent aging trajectories.
An international team analyzed genetic and health data from hundreds of thousands of participants using multivariate genome-wide association methods. By examining 30 commonly measured frailty indicators, the researchers identified 408 genomic loci associated with accelerated biological aging and frailty—far more than previously known.
Rather than treating frailty as a single score, the study modeled a general frailty factor along with six specific genetic factors that correspond to different clusters of deficits. Those clusters highlight distinct biological mechanisms linked to particular forms of unhealthy aging, such as cognitive deterioration, metabolic risk, or functional disability.
Redefining frailty
Frailty is commonly described as multisystem physiological decline. Clinicians often use an accumulated-deficit index—composed of measures like walking speed, grip strength, diagnosed conditions, and social engagement—to estimate frailty. But aggregate scores can mask important differences: two people with the same overall frailty score may have very different profiles and underlying causes.
The study addresses this problem by separating genetic signals tied to specific clusters of frailty symptoms. For example, variation in the SP1 gene—implicated in immune function and linked to Alzheimer’s disease—was strongly associated with the poor cognition subtype. The FTO gene, known for its role in body weight and obesity, contributed to multiple frailty categories, especially those related to metabolic risk.
“Aging is not just one thing. There are many ways to be frail,” said Dr. Kenneth Rockwood, co-author and frailty expert. Identifying subtype-specific genes helps clarify the biological pathways that lead to different age-related problems and points toward more precise interventions.
Implications for prevention and treatment
In the near term, the authors recommend expanding clinical frailty assessments to include these six subtypes. Doing so would enable clinicians to tailor prevention and treatment: someone identified as cognitively frail could be prioritized for dementia-prevention strategies, while a person with metabolic frailty might receive targeted interventions for diabetes or cardiovascular risk.
Researchers also envision developing polygenic risk scores that detail an individual’s predisposition toward specific aging patterns. That information could inform lifestyle changes, monitoring, and early therapeutic interventions.
As for a single “anti-aging” pill that cures all age-related diseases, the study suggests that is unlikely. Instead, the findings point toward a smaller number of targeted therapies—each addressing particular biological pathways that drive clusters of age-related conditions. “It’s probably not going to be a single magic pill,” said senior author Andrew Grotzinger, “but we may not need hundreds either.”
Author: Lisa Marshall
Source: University of Colorado
Contact: Lisa Marshall – University of Colorado
Image: Image credited to Neuroscience News
Original Research: Closed access. Title: “Uncovering the multivariate genetic architecture of frailty with genomic structural equation modeling” by Isabelle Foote et al., published in Nature Genetics. DOI reference: 10.1038/s41588-025-02269-0
Abstract (summarized)
Frailty is a multifaceted clinical state linked to accelerated aging and poor health outcomes. Aggregate frailty scores obscure the specific etiological pathways that affect subsets of deficits. Using a multivariate genome-wide association approach across 30 frailty deficits, the study identifies 408 genomic risk loci and models a general genetic factor plus six subgroup-specific factors. These nuanced models improve prediction of frailty in external datasets, reveal divergent genetic correlations with clinical outcomes, and uncover distinct biological pathways related to aging. The results demonstrate that dissecting frailty into biologically meaningful subcomponents is essential to understanding its causes and guiding interventions.